Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Aditya Bardia(UCLA Health), Jennifer Friedmann, Hans Wildiers(KU Leuven), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Barbara Pistilli(Institut Gustave Roussy), Yen‐Shen Lu(National Taiwan University Hospital), Junji Tsurutani(SHOWA Medical University), Rick M. Fairhurst(National Institutes of Health), Pedro Emanuel Rubini Liedke(Massachusetts General Hospital), Hélio Pinczowski(Apple (Israel)), Marcelle Goldner Cesca, Liane Rapatoni, José Bines, Joëlle Collignon(Centre Hospitalier Universitaire de Liège), Kevin Punie(KU Leuven), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sònia Pernas, Laura Testa, Masaya Hattori(Aichi Cancer Center), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Kevin Kalinsky(Emory University), Jamil Asselah, David W. Cescon(Princess Margaret Hospital), Giuliano Borges, Sandra Anabel Ostoich, Seock‐Ah Im(Seoul National University), Sabrina S. Khan(AstraZeneca (Japan)), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Noelia Martínez-Jáñez(Instituto Cajal), Neelima Denduluri(Washington Hospital), Hope S. Rugo(City of Hope), Shusen Wang(Sun Yat-sen University), Joanne Yu(National Institutes of Health), Qingyuan Zhang(Harbin Medical University), Andrea Gombos, Ernesto Korbenfeld(Harbin Medical University), Betiana Romitelli, Geronimo Rosselli, Debora de Melo Gagliato Jardim, Lu Xu(AstraZeneca (Japan)), Andre Blais, Cristian Buono, Arturo Barbero, Erika Hamilton(Sarah Cannon), Sergio Daniele, Patrícia Medeiros Milhomem Beato
Cited by 163
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k